Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.
Twenty cats with spontaneously arising tumors received oral lomustine at a dose range of 32 to 59 mg/m2 every 21 days. Due to biohazard concerns associated with lomustine capsule reformulation, a standardized 10-mg capsule dosage was used for all cats regardless of body weight. Severe hematological toxicity was infrequent, with the incidence of either grade III or IV neutropenia and thrombocytopenia being 4.1% and 1.0%, respectively. Cats receiving higher cumulative doses of lomustine trended toward a greater likelihood for progressive neutropenia (P=0.07). Two cats with lymphoma, two cats with fibrosarcoma, and one cat with multiple myeloma achieved a measurable partial response to lomustine therapy. Cats treated with higher dosages of lomustine trended toward statistically significant higher response rates (P=0.07).
Department of Veterinary Medicine, Veterinary Medical Teaching Hospital, University of Illinois, Urbana 61802-4714, USA.
Timothy M
TM
Fan
Barbara E
BE
Kitchell
Ravinder S
RS
Dhaliwal
Pamela D
PD
Jones
John G
JG
Hintermeister
Biman C
BC
Paria
D000284:Administration, Oral; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000473:pathology; D002415:Cats; D004334:Drug Administration Schedule; D005354:Fibrosarcoma / Q000188:drug therapy / Q000662:veterinary; D008130:Lomustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary; D009101:Multiple Myeloma / Q000188:drug therapy / Q000662:veterinary; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D009503:Neutropenia / Q000139:chemically induced / Q000662:veterinary; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced / Q000662:veterinary; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D008130:Lomustine